FDA Clearance of CBC Marks a Defining Platform Milestone, Expanding TruVerus™ to 26 Cleared Assays and the first FDA clearance for CBC from a lithium heparin sample.
Truvian announced it has received 510(k) clearances from the U.S. FDA for nine additional analytes for TruVerus, the industry’s first FDA cleared multimodal benchtop blood analyzer.
Truvian announced the appointment of Michael J. Mina, MD, PhD as Chief Medical and Strategy Officer to oversee clinical and regulatory strategy, while advancing strategic partnerships and opportunities.
Truvian announced that the U.S. FDA has granted 510(k) clearance (K251058) for TruVerus™, the industry’s first multimodal blood testing benchtop instrument.
